Progesterone but not estradiol 17β potentiates local GH secretions by hormone-dependent breast cancer explants. An in vitro study

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 2, 2005, Pages 127-132

  Milewicz, T ^a   Gregoraszczuk, E L ^a   Augustowska, K ^a   Krzysiek, J ^a   Sztefko, K ^a   Rys, J ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cell proliferation; Estradiol; Human breast cancer explants; Local GH secretion; Progesterone

Indexed keywords

ESTRADIOL; GROWTH HORMONE; PROGESTERONE; TAMOXIFEN; HUMAN GROWTH HORMONE; LUTEINIZING HORMONE;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; EXPLANT; FEMALE; HORMONE DEPENDENCE; HORMONE RELEASE; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DRUG EFFECT; MASTECTOMY; PATHOLOGY; SECRETION;

BREAST NEOPLASMS; CELL DIVISION; ESTRADIOL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; LUTEINIZING HORMONE; MASTECTOMY, RADICAL; PROGESTERONE; TUMOR CELLS, CULTURED;

EID: 15244352431     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830556     Document Type: Article

References (34)

1. 3H] thymidine incorporation assay. J Immunol Methods 1994; 170: 211-224
2. Baldini E, Giannessi PG, Gardin G, Alama A, Minuto F, Barreca A, Conte PF. In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma. J Biol Regul Homeost Agents 1994; 8: 113-116
3. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427
4. Bontenbal M, Foekens JA, Lamberts SW, de Jong FH, van Putten WL, Braun HJ, Burghouts JT, van der Linden GH, Klijn JG. Feasibility, endocrine and anti-tumor effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer 1998; 77: 115-122
5. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98: 498-508
6. Clarke R, Skaar T, Baumann K, Leonessa F, James M, Lippman J, Thompson EW, Freter C, Brunner N. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat 1994; 31: 237-248
7. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990; 11: 266-301
8. Croce MV, Colussi AG, Segal-Eiras A. Assessment of methods for primary tissue culture of human breast epithelia. J Exp Clin Cancer Res 1998; 17: 19-26
9. Dao TL, Sinha DK, Nemoto T, Patel J. Effect of estrogen and progesterone on cellular replication of human breast tumors. Cancer Res 1982; 42: 359-362
10. Dixon JM. Hormone replacement therapy: is it safe for breast cancer patients? MJA 2002; 177: 340-341
11. 3H-thymidine incorporation assay. J Clin Lab Anal 1995; 9: 89-95
12. Gebre-Medhin M, Kindblom LG, Wennbo H, Tornell J, Meis-Kindblom JM. Growth hormone receptor is expressed in human breast cancer. Am J Pathol 2001; 158: 1217-1222
13. Gregoraszczuk EL, Milewicz T, Kolodziejczyk J, Krzysiek J, Basta A, Sztefko K, Kurek S, Stachura J. Progesterone-induced secretion of growth hormone, insulin-like growth factor 1 and prolactin by human breast cancer explants. Gynecol Endocrinol 2001; 15: 251-258
14. Horwitz KB. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 1992; 13: 146-163
15. Ishikawa T, Inoue S, Kakinuma C, Kuwayama C, Hamada Y, Shibutani Y. Growth-stimulating effect of dienogest, a synthetic steroid, on rodent, canine, and primate mammary glands. Toxicology 2000; 151: 91-101
16. Kajdaniuk D, Marek B, Kos-Kudla B, Buntner B, Zwirska-Korczala K, Ostrowska Z, Nowak M. Growth hormone and its interactions with chosen parameters of hormonal state in pre-menopausal women after mastectomy for breast cancer on adjuvant chemotherapy. Wiadomósci Lekarskie 2000; 53: 238-283
17. Kaulsay KK, Mertani HC, Tornell J, Morel G, Lee KO, Lobie PE. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res 1999; 250: 35-50
18. Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 1998; 273: 31308-31316
19. Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 1999; 13: 29-36
20. Lantinga-van Leeuwen IS, van Garderen E, Rutteman GR, Mol JA. Cloning and cellular localization of the canine progesterone receptor: colocalization with growth hormone in the mammary gland. J Steroid Biochem Mol Biol 2000; 75: 219-228
21. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ, Ho KK. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 2003; 100: 1016-1021
22. Lippman M, Bolan G, Huff K. The effects of glucocrti-coids and progesterone on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36: 4602-4608
23. Mandala M, Moro C, Ferretti G, Calabro MG, Nole F, Rocca A, Munzone E, Castro A, Curigliano G. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Anticancer Res 2001; 21: 585-588
24. Milewicz T, Kołodziejczyk J, Basta A, Kurek S, Sztefko K, Krzysiek J, Gregoraszczuk EL. Growth hormone (GH) induced local insulin-like growth factor 1 (IGF-I) secretion by human breast cancer explants. Pol J Gynaecol Invest 2001; 4: 61-65
25. Milewicz T, Kolodziejczyk J, Krzysiek J, Basta A, Sztefko K, Kurek S, Stachura J, Gregoraszczuk EL. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor 1 secretion stimulators then progesterone in human breast cancer explants expressing the estrogen receptor. Gynecol Endocrinol 2002; 16: 319-329
26. Nakayama GR, Caton MC, Nova MP, Parandoosh Z. Assesment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods 1997; 204: 205-208
27. Raafat AM, Hofseth LJ, Haslam SZ. Proliferate effects of combination estrogen and progesterone replacement therapy on the normal post-menopausal mammary gland in a murine model. Am J Obstet Gynecol 2001; 184: 340-349
28. Richer JK, Lagne CA, Manning NG, Owen G, Powell R, Horwitz KB. Convergence of progesterone with growth factor and cytokine signalling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 1998; 273: 31317-31326
29. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen vs. estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-332
30. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
31. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 284: 691-694
32. Swanson SM, Unterman TG. The growth hormone-deficient spontaneous dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis 2002; 23: 977-982
33. Tannenbaum GS, Gurd W, Lapointe M, Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 1992; 130: 3395-3401
34. Vignon F, Bardon S, Chalbos D, Rochefort H. Antiestrogen effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrinol Metab 1983; 56: 1124-1130